Skip to content
OpenCapital
Get started

CytomX Therapeutics CTMX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Pfizer logo
PfizerPFE
——
Allogene Therapeutics logo
Allogene TherapeuticsALLO
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——
Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
——
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
——

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's available for sale securities debt securities current?
CytomX Therapeutics (CTMX) reported available for sale securities debt securities current of $317.88M in Q1 2026.
How has CytomX Therapeutics's available for sale securities debt securities current changed year-over-year?
CytomX Therapeutics's available for sale securities debt securities current increased by 884.7% year-over-year, from $32.28M to $317.88M.
What is the long-term trend for CytomX Therapeutics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), CytomX Therapeutics's available for sale securities debt securities current has grown at a 0.0% compound annual growth rate (CAGR), from $124.26M to $124.39M.